12/11/2023 | CV | Evolent Health greenshoe ups six-year convertibles to $402.5 million
|
12/7/2023 | CV | Market Commentary: Nikola convertibles on tap, maybe; Repligen gains; Evergy active; Evolent down outright
|
12/6/2023 | CV | Market Commentary: Nikola on deck; Merit Medical, Sphere Entertainment, Evolent in focus, expand on debut
|
12/6/2023 | CV | Market Commentary: Morning Commentary: Merit Medical, Sphere Entertainment, Evolent price, expand on debut
|
12/6/2023 | CV | New Issue: Evolent Health sells $350 million six-year convertible notes to yield 3.5%, up 42.5%
|
12/5/2023 | CV | Market Commentary: Sphere, Evolent, Merit convertible offerings play to strong demand; Evergy up on debut
|
12/5/2023 | BK | Evolent Health to use proceeds to prepay term loan due January 2029
|
12/5/2023 | CV | Market Commentary: Morning Commentary: Sphere, Evolent, Merit convertibles eyed; Evergy strong on debut
|
12/5/2023 | CV | Evolent Health talks $350 million six-year convertibles to yield 3.25%-3.75%, up 37.5%-42.5%
|
8/4/2023 | CVLM | Evolent Health calls all $24.3 million 3.5% convertibles due 2024
|
1/23/2023 | BKPV | Evolent Health obtains total of $265 million in incremental funding
|
6/29/2022 | PV | Evolent Health will borrow $225 million credit facility for acquisition
|
4/13/2022 | SP | New Issue: JPMorgan sells $145,000 capped buffered equity notes on basket of 28 biotech stocks
|
8/14/2020 | CV | Market Commentary: iQIYI convertible notes contract following SEC investigation; Farfetch tops double par
|
8/14/2020 | CVLM | Evolent exchanges $84.2 million of 2% convertibles for new notes
|
12/31/2019 | BK | Evolent Health obtains $75 million initial term loan, up to $50 million delayed-draw term loan
|
5/29/2019 | CV | Market Commentary: MFA Financial, Enphase on tap; InterDigital convertibles eyed; Tesla, Evolent active
|
10/23/2018 | CV | Evolent Health greenshoe lifts 1.5% convertibles to $172.5 million
|
10/19/2018 | CV | Market Commentary: Convertibles activity muted; Cleveland-Cliffs contracts post-earnings; Citrix active
|
10/19/2018 | CV | Market Commentary: Morning Commentary: Convertibles activity muted; Cleveland-Cliffs active post-earnings
|
10/18/2018 | CV | Market Commentary: Evolent Health hits the market; Aegean Marine notes eyed; Ligand, Exact Sciences active
|
10/18/2018 | CV | Market Commentary: Morning Commentary: Evolent Health hits the market; Aegean Marine Petroleum notes eyed
|
10/18/2018 | CV | New Issue: Evolent sells upsized $150 million seven-year convertibles to yield 1.5%, up 32.5%
|
10/17/2018 | CV | Market Commentary: Evolent convertibles eyed; Caesars notes drop dollar-neutral; Cree, Herbalife active
|
10/17/2018 | CV | Market Commentary: Morning Commentary: Primary market eyes Evolent Health convertibles; Cree notes in focus
|
10/16/2018 | CV | Market Commentary: Evolent Health on tap; Twilio convertibles expand on volatility spike; Pandora improves
|
10/16/2018 | CV | Evolent Health talks $125 million seven-year convertible notes to yield 1.25%-1.75%, up 30%-35%
|
3/21/2017 | SP | New Issue: JPMorgan prices $1 million 9% three-month yield notes tied to Evolent
|
12/5/2016 | CV | Evolent Health greenshoe ups 2% five-year convertibles to $125 million
|
11/30/2016 | CV | Market Commentary: Newpark brings downsized deal with upsized coupon; Evolent Health trades up; energy pushes higher
|
11/30/2016 | CV | Market Commentary: Morning Commentary: Newpark brings downsized deal with upsized coupon; Evolent Health trades up
|
11/30/2016 | CV | New Issue: Evolent Health sells $110 million five-year convertibles to yield 2%, up 27.5%
|
11/29/2016 | CV | Market Commentary: OPEC concerns pressure crude prices, energy-linked convertibles; AMD firms; primary eyed
|
11/29/2016 | CV | Evolent Health offers $110 million five-year convertible senior notes
|